Methotrexate subcutaneous injection - Nordic Group

Drug Profile

Methotrexate subcutaneous injection - Nordic Group

Alternative Names: Nordimet; Zlatal®

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Nordic Group
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rheumatoid arthritis

Most Recent Events

  • 16 Nov 2016 Methotrexate subcutaneous injection licensed to Cumberland in USA
  • 18 Aug 2016 Launched for Rheumatoid arthritis in European Union (SC) after August 2016
  • 18 Aug 2016 Registered for Rheumatoid arthritis in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top